[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2000058339A3 - 50 proteines humaines secretees - Google Patents

50 proteines humaines secretees Download PDF

Info

Publication number
WO2000058339A3
WO2000058339A3 PCT/US2000/007440 US0007440W WO0058339A3 WO 2000058339 A3 WO2000058339 A3 WO 2000058339A3 US 0007440 W US0007440 W US 0007440W WO 0058339 A3 WO0058339 A3 WO 0058339A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
human secreted
proteins
novel human
relates
Prior art date
Application number
PCT/US2000/007440
Other languages
English (en)
Other versions
WO2000058339A2 (fr
Inventor
Craig A Rosen
Steven M Ruben
George Komatsoulis
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven M Ruben
George Komatsoulis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002368281A priority Critical patent/CA2368281A1/fr
Priority to AU37655/00A priority patent/AU3765500A/en
Priority to JP2000608039A priority patent/JP2003535570A/ja
Priority to EP00916566A priority patent/EP1220947A2/fr
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven M Ruben, George Komatsoulis filed Critical Human Genome Sciences Inc
Publication of WO2000058339A2 publication Critical patent/WO2000058339A2/fr
Priority to US10/105,299 priority patent/US7368527B2/en
Priority to US10/472,964 priority patent/US20070032414A1/en
Priority to US10/472,965 priority patent/US20070026454A1/en
Publication of WO2000058339A3 publication Critical patent/WO2000058339A3/fr
Priority to US10/670,185 priority patent/US20070015162A1/en
Priority to US10/670,186 priority patent/US20070031842A1/en
Priority to US10/868,184 priority patent/US20070048818A1/en
Priority to US10/994,608 priority patent/US20070048297A1/en
Priority to US11/781,665 priority patent/US20070298491A1/en
Priority to US12/753,401 priority patent/US8410248B2/en
Priority to US13/848,789 priority patent/US20130203164A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)

Abstract

L'invention concerne 50 nouvelles protéines humaines sécrétées et des acides nucléiques isolés contenant les zones de codage des gènes codant ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des méthodes de recombinaison permettant de produire des protéines humaines sécrétées. L'invention se rapporte en outre à des méthodes diagnostiques et thérapeutiques utiles dans le diagnostic et le traitement de maladies, de troubles, et/ou d'états pathologiques liés à ces nouvelles protéines humaines sécrétées.
PCT/US2000/007440 1999-03-12 2000-03-22 50 proteines humaines secretees WO2000058339A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002368281A CA2368281A1 (fr) 1999-03-26 2000-03-22 50 proteines humaines secretees
AU37655/00A AU3765500A (en) 1999-03-26 2000-03-22 50 human secreted proteins
JP2000608039A JP2003535570A (ja) 1999-03-26 2000-03-22 ５０個のヒト分泌タンパク質
EP00916566A EP1220947A2 (fr) 1999-03-26 2000-03-22 50 proteines humaines secretees
US10/105,299 US7368527B2 (en) 1999-03-12 2002-03-26 HADDE71 polypeptides
US10/472,964 US20070032414A1 (en) 1999-03-12 2002-03-26 Human secreted proteins
US10/472,965 US20070026454A1 (en) 1999-03-12 2002-03-26 Human secreted proteins
US10/670,185 US20070015162A1 (en) 1999-03-12 2003-09-25 99 human secreted proteins
US10/670,186 US20070031842A1 (en) 1999-03-12 2003-09-25 379 human secreted proteins
US10/868,184 US20070048818A1 (en) 1999-03-12 2004-06-16 Human secreted proteins
US10/994,608 US20070048297A1 (en) 1999-03-12 2004-11-23 Human secreted proteins
US11/781,665 US20070298491A1 (en) 1999-03-12 2007-07-23 Human Secreted Proteins
US12/753,401 US8410248B2 (en) 1999-03-12 2010-04-02 HWBAO62 polypeptides
US13/848,789 US20130203164A1 (en) 1999-03-12 2013-03-22 Human Secreted Proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12650399P 1999-03-26 1999-03-26
US60/126,503 1999-03-26
US17240999P 1999-12-17 1999-12-17
US60/172,409 1999-12-17

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/007505 Continuation-In-Part WO2000058467A1 (fr) 1999-03-12 2000-03-22 50 proteines humaines secretees
PCT/US2000/007506 Continuation-In-Part WO2000058513A1 (fr) 1999-03-12 2000-03-22 Quarante-neuf proteines humaines secretees

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2000/007505 Continuation-In-Part WO2000058467A1 (fr) 1999-03-12 2000-03-22 50 proteines humaines secretees
PCT/US2000/007506 Continuation-In-Part WO2000058513A1 (fr) 1999-03-12 2000-03-22 Quarante-neuf proteines humaines secretees
US95008201A Continuation-In-Part 1999-03-12 2001-09-12
US95008301A Continuation-In-Part 1999-03-12 2001-09-12

Publications (2)

Publication Number Publication Date
WO2000058339A2 WO2000058339A2 (fr) 2000-10-05
WO2000058339A3 true WO2000058339A3 (fr) 2002-05-10

Family

ID=26824730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007440 WO2000058339A2 (fr) 1999-03-12 2000-03-22 50 proteines humaines secretees

Country Status (5)

Country Link
EP (1) EP1220947A2 (fr)
JP (1) JP2003535570A (fr)
AU (1) AU3765500A (fr)
CA (1) CA2368281A1 (fr)
WO (1) WO2000058339A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847550A3 (fr) * 2001-07-19 2008-01-09 Nymox Corporation Peptides actives dans le traitement des tumeurs et autre conditions requérant la suppression ou la destruction de cellules
EP1417227B1 (fr) * 2001-07-19 2007-01-10 Nymox Corporation Peptides efficaces dans le traitement de tumeurs et d'autres etats pathologiques necessitant l'ablation ou la destruction de cellules
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2006339072A1 (en) 2005-03-14 2007-10-25 Board Of Regents Of The University Of Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOUKAS ET AL.: "A family of secreted mucins from the parasitic nematode toxocara canis bears diverse mucin domains but shares similar flanking six-cysteine repear motifs", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 50, December 2000 (2000-12-01), pages 39600 - 39607, XP002940088 *

Also Published As

Publication number Publication date
EP1220947A2 (fr) 2002-07-10
WO2000058339A2 (fr) 2000-10-05
JP2003535570A (ja) 2003-12-02
CA2368281A1 (fr) 2000-10-05
AU3765500A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
EP1053245A4 (fr) 45 proteines humaines secretees
WO1998039446A3 (fr) 70 proteines humaines secretees
WO1998039448A3 (fr) 186 nouvelles proteines secretees
WO1998040483A3 (fr) 28 proteines secretees par l'homme
WO1998031800A3 (fr) Proteines humaines
WO2001032910A3 (fr) 27 proteines humaines secretees
WO2001036432A3 (fr) 18 proteines secretees humaines
WO1998045712A3 (fr) 20 proteines humaines secretees
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
WO2001034768A3 (fr) 15 proteines secretees humaines
WO2001012776A3 (fr) 18 proteines secretees humaines
WO2000017222A8 (fr) 31 proteines humaines secretees
WO2000077026A8 (fr) 49 proteines secretees humaines
WO2000052136A3 (fr) Enzymes de glycosylation humaines
WO2000063230A3 (fr) 49 proteines secretees humaines
WO2000073323A3 (fr) Polynucléotides et polypeptides adam
WO2001062891A3 (fr) 207 proteines humaines secretees
EP1042342A4 (fr) 53 proteines secretees humaines
WO2000058339A3 (fr) 50 proteines humaines secretees
WO2001012775A3 (fr) 25 proteines secretees humaines
WO2000061624A8 (fr) 48 proteines secretees humaines
WO2000043495A3 (fr) Proteines humaines secretees (33)
WO2000061596A8 (fr) 50 proteines humaines secretees
WO2003052377A9 (fr) 41 proteines secretees humaines
WO2002099066A3 (fr) 20 proteines humaines secretees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 608039

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2368281

Country of ref document: CA

Ref country code: CA

Ref document number: 2368281

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916566

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000916566

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000916566

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)